Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company seeking to advance targe...
AVEO Pharmaceuticals, Inc. is a biopharmaceutic...
Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical compan...
Hepion Pharmaceuticals (Nasdaq: HEPA) is a clin...
Intersect ENT (NASDAQ: XENT) is a medical technology company dedicated to advancin...
Intersect ENT (NASDAQ: XENT) is a medical techn...
Theravance Biopharma is a diversified biopharmaceutical company with the core purp...
Theravance Biopharma is a diversified biopharma...
PhorMed is a clinical stage biopharmaceutical company located in Beverly Hills Cal...
PhorMed is a clinical stage biopharmaceutical c...
Dicerna is a biopharmaceutical company focused on the discovery and development of...
Dicerna is a biopharmaceutical company focused ...
Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a no...
Bicycle Therapeutics is a clinical-stage biopha...
Join the National Investor Network and get the latest information with your interests in mind.